(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.31%) $82.75
(6.40%) $2.05
(0.03%) $2 348.00
(-0.22%) $27.48
(3.94%) $958.40
(-0.25%) $0.932
(-0.34%) $10.99
(-0.56%) $0.796
(1.66%) $93.40
-2.27% $ 3.02
Live Chart Being Loaded With Signals
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies...
Stats | |
---|---|
Tagesvolumen | 1.01M |
Durchschnittsvolumen | 167 616 |
Marktkapitalisierung | 108.71M |
EPS | $0 ( 2024-03-28 ) |
Last Dividend | $0.130 ( 2015-11-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.25 |
ATR14 | $0.0570 (1.89%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Leonard Braden Michael | Buy | 170 589 | Common Stock, par value $0.001 per share |
2024-03-18 | Leonard Braden Michael | Buy | 113 777 | Common Stock, par value $0.001 per share |
2024-03-15 | Leonard Braden Michael | Buy | 0 | Common Stock, par value $0.001 per share |
2024-03-15 | Leonard Braden Michael | Sell | 0 | Common Stock, par value $0.001 per share |
2024-03-04 | Gaiero David G | Buy | 2 373 | Common Stock |
INSIDER POWER |
---|
11.39 |
Last 95 transactions |
Buy: 1 923 587 | Sell: 1 715 632 |
Volumen Korrelation
Cyteir Therapeutics, Inc. Korrelation
10 Am meisten positiv korreliert | |
---|---|
EBACU | 0.891 |
TCMD | 0.875 |
ECHO | 0.873 |
TZPSU | 0.872 |
WULF | 0.871 |
TZPS | 0.869 |
JNCE | 0.869 |
MBTCU | 0.868 |
RBNC | 0.866 |
NLTX | 0.865 |
10 Am meisten negativ korreliert | |
---|---|
VIASP | -0.896 |
STBA | -0.894 |
CMBM | -0.893 |
FBNC | -0.893 |
MMAC | -0.893 |
TRST | -0.892 |
LSAQ | -0.891 |
CVCY | -0.891 |
OPI | -0.891 |
VGFC | -0.891 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Cyteir Therapeutics, Inc. Korrelation - Währung/Rohstoff
Cyteir Therapeutics, Inc. Finanzdaten
Annual | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $-1.38M (0.00 %) |
EPS: | $-1.250 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $-1.38M (0.00 %) |
EPS: | $-1.250 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.201 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Cyteir Therapeutics, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0100 | 2009-08-06 |
Last Dividend | $0.130 | 2015-11-06 |
Next Dividend | $0 | N/A |
Payout Date | 2015-11-25 | |
Next Payout Date | N/A | |
# dividends | 26 | -- |
Total Paid Out | $2.66 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.76 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.236 | 1.200 | -7.86 | -9.43 | [0 - 0.3] |
returnOnEquityTTM | -0.231 | 1.500 | -3.68 | -5.52 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 21.89 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 21.66 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 21.65 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.000122 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 39.40 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.716 | 2.00 | -0.239 | -0.477 | [0 - 30] |
freeCashFlowPerShareTTM | -0.724 | 2.00 | -0.362 | -0.724 | [0 - 20] |
debtEquityRatioTTM | 0.000128 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1 611.81 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.52 | 1.000 | -0.457 | 0 | [1 - 100] |
returnOnEquityTTM | -0.231 | 2.50 | -2.37 | -5.52 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.724 | 2.00 | -0.241 | -0.724 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.716 | 2.00 | -0.239 | -0.477 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.983 |
Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.